Clinical Trials Sponsored by Incyte Corporation

Total 6563 results

Incyte Corporation

Completed

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Solid Tumors

Japan
Incyte Corporation

Completed

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Incyte Corporation

Withdrawn

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Pemphigus Vulgaris
Incyte Corporation

Completed

Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Pancreatic Cancer | Solid Tumors

United States
Incyte Corporation

Terminated

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Melanoma

United States
Incyte Corporation

Completed

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Puerto Rico
Incyte Corporation

Terminated

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs (DECLARE)

HIV Infections | Human Immunodeficiency Virus

United States, Puerto Rico
Incyte Corporation

Completed

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Type 2 Diabetes

United States, Puerto Rico
Incyte Corporation

Completed

Study of Ruxolitinib in Pancreatic Cancer Patients (RECAP)

Pancreatic Cancer

United States
Incyte Corporation

Terminated

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

Breast Cancer

India
Incyte Corporation

Completed

A Dose-escalation Study in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States
Incyte Corporation

Terminated

INCB047986 in Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Incyte Corporation

Completed

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Myelofibrosis

United States
Incyte Corporation

Completed

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Obesity | Insulin Resistance

United States
Incyte BioSciences France

Completed

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Chronic Myeloid Leukemia

France
Incyte Biosciences Benelux

Completed

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Chronic Myeloid Leukemia | CML | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Ph+ ALL

Belgium
Incyte Corporation
AstraZeneca

Completed

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Head and Neck Cancer | Lung Cancer | Solid Tumors | UC (Urothelial Cancer)

United States
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
Oncotherapeutics
Incyte Corporation

Not yet recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma
Oncotherapeutics
Incyte Corporation

Recruiting

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Multiple Myeloma

United States
Incyte Corporation
AstraZeneca

Active, not recruiting

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Lung Cancer

United States, Korea, Republic of, Spain, Taiwan
Pfizer
Incyte Corporation

Completed

A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers

Healthy

United States
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Incyte Biosciences Japan GK

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Incyte Biosciences International Sàrl

Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Lymphoma | Acute Myeloid Leukemia | Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Solid Tumors | Chronic Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia

Spain, Italy, France, Germany, United Kingdom, Belgium, Sweden, Denmark, Netherlands
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Incyte Biosciences International Sàrl

Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States, Belgium, Australia, Spain
Incyte Biosciences International Sàrl

Completed

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States, United Kingdom, Spain, Switzerland
Incyte Biosciences Japan GK

Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Lymphoma

Japan
Incyte Biosciences Japan GK

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Solid Tumors

Japan
Incyte Biosciences Japan GK

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

Healthy Participants

Japan
Incyte Biosciences International Sàrl

Completed

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States
Emory University
Incyte Corporation

Recruiting

Virtual Rehabilitation in HCT

Hematopoietic Cell Transplant

United States
Columbia University
Incyte Corporation

Active, not recruiting

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

United States
Incyte Corporation
Innovaderm Research

Completed

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Atopic Dermatitis

United States
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Incyte Corporation
Novartis Pharmaceuticals

Completed

A Dose-escalation Study in Subjects With Advanced Malignancies

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
University of Zurich
Incyte Corporation

Not yet recruiting

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities (TRUX-LST)

Exanthema | Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
University of Washington
Incyte Corporation

Recruiting

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (TRICK-MCC)

Merkel Cell Carcinoma | Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

United States
Pfizer
Incyte Corporation; MorphoSys AG

Recruiting

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

United States, Japan, Puerto Rico, Korea, Republic of
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States

Clinical Trials Sponsored by Incyte Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations